Rebuilding Bones, Repairing Lives: Immunity and RNA Therapies – Prof. Martijn van Griensven
What does it take to lead the future of regenerative medicine? Professor Martijn van Griensven shared the experiences that have shaped his journey from his early days as Germany’s youngest professor to his current work as a leading mind in biomedical research and head of the cBITE department at the MERLN Institute.We explored how bones heal, and why sometimes they don’t, and what role the immune system plays when regeneration breaks down. We dove into the molecular world of RNA therapies and their potential to modulate immune responses and help tissues rebuild themselves.We talked about the practical challenges of bringing these therapies into the clinic, the role of AI in tailoring treatments to each patient, and what the future might hold. For Professor van Griensven, it’s not just about molecules and machines, it’s about curiosity, perseverance, and asking the right questions.If you want to learn more, please follow the links below:MERLN Institute for Technology-Inspired Regenerative Medicine: https://merlninstitute.comHannover Medical School: https://www.mhh.de/en/Research paper on the patient case after the motorcycle accident: https://www.cureus.com/articles/246346-the-treatment-of-very-large-traumatic-bone-defects-of-the-tibia-with-a-polycaprolactone-tricalcium-phosphate-3d-printed-cage-a-review-of-three-cases#!/Timestamps:00:00 Intro Biomed Unleashed00:27 Guest Introduction00:55 Welcome1:10 Academic background2:20 Challenges of being the Youngest Professor in Germany – 26 years old!3:43 What initially sparked Martijn’s interest in regenerative medicine? – US experience6:25 Why did Martijn start working at MERLN Institute for Technology-Inspired Regenerative Medicine in Maastricht, the Netherlands?8:05 Why bone cannot heal on its own when there is a large defect?9:56 Main ways to help the bone to heal? Does immunity play a role in that?11:47 Most promising way to regenerate bones13:14 RNAs and RNA-based regenerative medicine therapies15:43 What type of RNA therapies is the focus of Martijn’s research?16:55 Differences between messenger RNAs and micro RNAs18:56 Are messenger RNAs or micro RNAs better?20:13 Off-target effects of micro RNAs?21:59 Can micro RNAs help stem cells avoid immune rejection in the human body? 25:01 If one type of micro RNAs is considered safe for human use, does it mean that other types are safe as well or are they completely different?26:20 How can environmental factors affect micro RNAs in stem cells?28:11 3D culture environment for micro RNAs. Is that important and is it used in research?30:25 Microfluidic systems to study microRNA activity32:00 Influence of specific materials for bone regeneration on micro RNA activity34:01 Antagomirs – what are they and how are they used in regenerative medicine?36:31 Challenges when using antagomirs38:16 Are microRNAs specific or have multiple targets in the body?39:52 Delivery systems of micro RNAs to cells42:19 Gene editing tools to modify micro RNAs – is it possible?42:39 Challenges of gene editing tools44:21 Regenerative medicine in 5-10 years45:39 Which countries are leading regenerative medicine research?47:05 Exciting upcoming projects at MERLN Institute for Technology-Inspired Regenerative Medicine in Maastricht, the Netherlands48:37 What is a research project that Martijn is most proud of?49:49 How did regenerative medicine therapy heal 15 cm bone defect after a motorcycle accident?!51:08 Minimum bone defect size that bone cannot heal anymore on its own51:53 AI in regenerative medicine53:30 AI in personalized medicine54:43 Skills that students need to possess to work in regenerative medicine field56:16 Last question!57:30 Conclusion57:43 Meet Biomed Unleashed Team58:06 Outro Biomed UnleashedHosts and writers: Alisa Ovsiannikova, Alba Villagrasa MartinEditor: Misha BagirovPromotion: Amalia BagdasaryanCoordinator: Alisa OvsiannikovaMERLN Institute for Technology-Inspired Regenerative Medicine
--------
58:21
--------
58:21
Commercialization of Regenerative Medicine Research – Prof. Marianne van der Steen
How do you commercialize regenerative medicine, and why is it so challenging? What does it take to build a successful biotech startup? And are revolutionary regenerative medicine solutions closer than we think?In this episode, our guest is Marianne van der Steen, Professor of Entrepreneurship in Healthcare and Chief Business Development Officer at the MERLN Institute for Technology-Inspired Regenerative Medicine in the Netherlands. Prof. van der Steen is a founding director of REGMED XB, a translational institute with an investment of 250 million euros, which translates groundbreaking regenerative medicine technologies into commercial products and companies.Her expertise spans across not only research in biomedical entrepreneurship, but also translation of regenerative medicine into market-ready solutions, co-founding of game-changing ventures, and bridging the gap between scientists, businesspeople, and policymakers. With over 15 years of experience in scaling regenerative medicine startups, mentoring entrepreneurs, and making transatlantic collaboration possible, she is the one shaping the future of regenerative medicine.If you want to learn more about the companies and institutes mentioned in the episode, please follow the links below:MERLN Institute for Technology-Inspired Regenerative Medicine –https://merlninstitute.comRegMed XB –https://regmedxb.comCalifornia Institure for Regenerative Medicine (CIRM) –https://www.cirm.ca.gov MIRA University of Twente –https://www.utwente.nl/en/news/2010/3/116725/mira-ambitious-plan-for-the-future Hummingbird Biomedical –https://www.hummingbirdbiomedical.com ReGen Biomedical – https://www.regenbiomedical.com Vertex Pharmaceuticals –https://www.vrtx.com/home/Mayo Clinic –https://www.mayoclinic.orgNextkidney –https://nextkidney.comTimestamps:00:00 Introduction to Biomed unleashed00:39 Guest Introduction01:32 Welcome01:45 What has inspired you to focus on valorization of scientific knowledge?03:35 Why valorization of specifically regenerative medicine projects?05:14 Why is it challenging to commercialize regenerative medicine compared to other fields?07:23 What is the idea behind the RegMed XB company that you co-founded?09:34 What are the Moonshots in RegMed XB company, and why these specific Moonshots were chosen?12:00 How do you foster international and public-private collaborations within regenerative medicine field?14:29 What stage of product development are you typically involved in?17:05 Do you teach scientists entrepreneurial skills?20:08 What advice would you give to scientists who aspire to bring their knowledge to commercial applications?22:34 How do you tackle failures, and what is a failure?27:30 Why and how transatlantic collaboration between US and the Netherlands is important in the regenerative medicine field?32:08 Looking into the future, how close are we to treating patients with engineered/artificial/lab-grown human tissues?36:47 Future of in-silico trials38:34 How can we measure success?41:06 What is the most successful project you helped to upscale?43:14 Last question!45:15 Final thoughts46:09 Meet Biomed Unleashed Team46:37 Biomed Unleashed Outro
--------
46:53
--------
46:53
Genetic Approach to Regenerative Medicine – Prof. David Schaffer
How do you get hold of the viruses and, with their help, cure some of the deadliest diseases known to humanity?
In this episode, David Schaffer, Professor of Chemical and Bioengineering, and Cell and Molecular Biology at the University of California, Berkeley, who was the first scientist to apply the directed evolution to engineer viruses for gene therapy, will share with us some of the most exciting parts of his academic journey in chemical and biomolecular engineering!
What is the process of directed evolution and how did it advance the field of gene therapy?
Were there any unexpected findings at David Schaffer’s Laboratory that led to groundbreaking discoveries?
How did the experience in founding and leading biotech companies affect his approach to academic research?
In this episode, discover the answers to these questions and get more insights into David Schaffer’s academic life!
Hosts and writers: Alisa Ovsiannikova, Misha Bagirov
Editors: Alisa Ovsiannikova, Misha Bagirov
Promotion: Amaliya Bagdasaryan
Coordinator: Alisa Ovsiannikova
--------
52:18
--------
52:18
Bioengineering meets personalized medicine – Prof. Ali Khademhosseini
What is personalised medicine and how it revolutionizes our understanding of classic medical approaches?
In this Episode, Professor Ali Khademhosseini, the CEO, and Terasaki Distinguished Professor at the Terasaki Institute in Los Angeles, USA, guides us through his scientific journey in bioengineering and personalized medicine.
Prof. Ali Khademhosseini was cited more than 133.000 times and has an H-index of 190. He has been honored by more than 70 major awards at both national and international levels.
What motivated Prof. Ali Khademhosseini to join Terasaki institute and reform it into a new research organisation, focusing on real-life applications of tissue engineering?
How did Ali Khademhosseini’s successful transition from academia to industry unleash?
How are hydrogels and organs-on-a-chip revolutionizing the field of personalized medicine?
Which personalized biomedical device has the highest potential to come next to clinical application?
You will find the answers to these questions and many more groundbreaking and inspiring insights on Ali Khademhosseini’s career in this episode!
Hosts and writers: Alisa Ovsiannikova, Misha Bagirov
Editors: Alisa Ovsiannikova, Misha Bagirov
Promotion: Amaliya Bagdasaryan
Coordinator: Alisa Ovsiannikova
--------
36:56
--------
36:56
Path to Innovation - Prof. Robert Langer
In our new episode, tune in to one of the most influential figures in biomedical engineering, Professor Robert Langer!
This summer, Alisa Ovsiannikova and Misha Bagirov travelled all the way from the Netherlands to the US and visited MIT to conduct an incredible interview with Professor Robert Langer!
As the most cited engineer in history, with over 430,000 citations and an h-index of 326, Professor Langer's contributions to the fields of tissue engineering and drug delivery systems are unmatched. His work has created countless innovations with over 1,400 patents under Prof Langer’s name.
Join us as Professor Langer shares the journey that led him from a childhood chemistry kit to a groundbreaking career in chemical and biomedical engineering.
In this episode, Professor Langer opens up about the critical moments when his work began gaining acceptance, the challenges and triumphs of founding biotech companies like Moderna, and how his father’s wisdom shaped his unbeatable pursuit of innovation.
We also dive into the cutting-edge research happening at Langer Lab, the largest biomedical engineering lab in the world, as well as exciting advances in drug delivery systems and tissue engineering.
You can find all of that and many other exciting insights in our new episode!
Hosts and writers: Alisa Ovsiannikova, Misha Bagirov
Editors: Rossana Serlenga, Alisa Ovsiannikova, Misha Bagirov
Promotion: Amaliya Bagdasaryan
Coordinator: Alisa Ovsiannikova
Exploring the wonders of regenerative medicine with student hosts & expert guests.
Join us as we learn about the innovations in this exciting field!
BIOMED UNLEASHED TEAM: Alisa Ovsiannikova, Mikhail Bagirov, Alba Villagrasa Martin, Amalia Bagdasaryan, Nika Cindori, Rossana Serlenga, Elisey Melnikov
Netherlands